Stock Analysis
Cogent Biosciences, Inc. (COGT) Stock Analysis
Cogent Biosciences, Inc. (COGT) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Cogent Biosciences, Inc. (COGT) currently has an AIQ Score of 44/100, indicating a bearish setup. Risk is the strongest factor at 51/100. Quality is the weakest current factor at 40/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
COGT at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $28.56 |
| AIQ Score | 44/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $4.94B |
| P/E Ratio (TTM) | -12.31 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.59 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.38 |
| Volume | 1.15M |
| 52-week range | $27.74-$43.73 |
| RSI 14 | 40.78 |
| 50-Day SMA | $31.39 |
| 200-Day SMA | $35.30 |
| Analyst Price Target | — |
| Next Earnings | Feb 16, 2027 |
COGTCogent Biosciences, Inc.
Healthcare / Biotechnology
Low Priority
Above Peers
Latest quote
- Momentum45
- Value—
- Quality40
- Risk resilience51
- Sentiment—
COGT Stock Analysis Summary
Cogent Biosciences, Inc. (COGT) currently has an AIQ Score of 44/100, indicating a bearish setup. Risk resilience is the strongest factor at 51/100. Quality is the weakest current factor at 40/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, COGT has AIQ Score of 44/100 with Risk resilience base of 51/100 and fading Quality at 40/100. Wait for component alignment before adding exposure.
Healthcare · -1.99% stock move · COGT classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is COGT Bullish or Bearish Right Now?
COGT currently has a bearish overall setup. Risk Resilience is the strongest factor at 51/100, while Quality is weakest at 40/100. The current evidence suggests a bearish setup.
- - No strong bullish evidence is available in the current snapshot.
- - Momentum is weak at 45/100.
- - Price is -19.10% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (34 vs 9).
Current Consensus
COGT's Technical Analysis Consensus is currently Strong Sell, with 9 buy, 3 neutral, and 34 sell votes. COGT's 14-day RSI is 40.78, which places the stock in a weaker momentum range. COGT's beta is 1.38, indicating greater market sensitivity than the broad market.
What Changed in COGT?
The largest recent change in COGT is Momentum moving up by 3.0 points over the available 7-day comparison window. Risk Resilience remains the strongest visible factor.
What Would Change the COGT Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
COGT Decision Framework
Public evidence layers, setup checks, and risk context for Cogent Biosciences, Inc..
Cogent Biosciences, Inc. (COGT) Stock Analysis
Cogent Biosciences, Inc. has an AIQ Score of 44/100 in a Bearish regime. Risk is strongest at 51/100. Beta is 1.38, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | COGT is in a Bearish AIQ regime with score 44/100. |
| Signal Conflict | The primary conflict is that risk leads at 51/100 while quality lags at 40/100. |
| Factor Evidence | Momentum 45/100 · Quality 40/100 · Risk 51/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 51/100.
Momentum is 45/100 and RSI (14) is 40.8.
COGT is in a Bearish regime at 44/100.
Risk factor is 51/100 with beta 1.38 and annual volatility 45.96%.
Current conflict: risk leads at 51/100 while quality lags at 40/100.
COGT Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
COGT Fundamentals
COGT valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
COGT Technical Analysis
COGT technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
COGT Stock Catalysts
Track COGT earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
COGT Dividend Analysis
COGT dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
COGT Financial Data
COGT revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
COGT Risk Analysis
COGT volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
COGT Stock News
COGT stock news, market tone, recent headlines, and catalyst context.
COGT vs Biotechnology Peers
Current peer cohort: COGT · CYTK · DFTX · DNTH · DYN. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| COGT Current stock | 44/100 | — | 45/100 | 51/100 | -0.23 | 45.96% | Current |
| CYTK Cytokinetics, Incorporated | 40/100 | 41/100 | 28/100 | 56/100 | -0.23 | 43.65% | COGT vs CYTK |
| DFTX Definium Therapeutics, Inc. | 59/100 | — | 64/100 | 44/100 | 1.61 | 77.71% | COGT vs DFTX |
| DNTH Dianthus Therapeutics, Inc. | 56/100 | — | 58/100 | 58/100 | 1.82 | 59.79% | COGT vs DNTH |
| DYN Dyne Therapeutics, Inc. | 48/100 | — | 52/100 | 42/100 | 0.11 | 63.89% | COGT vs DYN |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for COGT: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching COGT
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for COGT
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
COGT Stock FAQ
What is COGT stock price today?
Cogent Biosciences, Inc.'s current stock price is $28.56. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is COGT bullish or bearish right now?
COGT's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is COGT's market cap?
COGT's market cap is $4.94B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is COGT's current P/E ratio?
COGT's current P/E ratio is -12.31 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is COGT's RSI?
COGT's 14-day RSI is 40.78 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is COGT above its 50-day and 200-day moving averages?
COGT is -9.02% from its 50-day SMA and -19.10% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is COGT's next earnings date?
COGT's next earnings date is currently listed as Feb 16, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does COGT pay a dividend?
COGT's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.